We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Highmark BCBS to Cover MDxHealth Prostate Cancer Test
News

Highmark BCBS to Cover MDxHealth Prostate Cancer Test

Highmark BCBS to Cover MDxHealth Prostate Cancer Test
News

Highmark BCBS to Cover MDxHealth Prostate Cancer Test

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Highmark BCBS to Cover MDxHealth Prostate Cancer Test"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MDxHealth SA has announced that the Highmark BCBS (Highmark) has issued a positive medical coverage policy decision for the ConfirmMDx® for Prostate Cancer test. This positive coverage policy is in line with the positive medical policy recently implemented by Independence Blue Cross and represents the second Blue Cross Blue Shield Association (BCBSA) licensee to establish coverage for commercial and Medicare members for ConfirmMDx.

Highmark is a national, diversified health care partner based in Pittsburgh that serves members across the United States through businesses in health insurance, dental insurance, vision care and reinsurance. Highmark, and its affiliates, operate health insurance plans in Pennsylvania, Delaware and West Virginia that serve 5.2 million members. Highmark is among the largest health insurers in the United States and is the fourth largest Blue Cross and Blue Shield-affiliated company.

"Highmark Blue Cross Blue Shield's positive policy decision adds to the momentum we are seeing in payer adoption of the ConfirmMDx for Prostate Cancer test," stated Dr. Jan Groen, CEO of MDxHealth. "This decision further validates the impact ConfirmMDx has on patient outcomes and reduction in cost to the US healthcare system."

Advertisement